Sprint Bioscience AB

SPRINT · Nasdaq Stockholm · Healthcare

3.53SEK −1.1%last day

Price as of 2 October 2026

The price over the past year, with dividends: +512.8%

Performance

1 month

+7.3%

1 year

+512.8%

3 years, per year

+24.0%

5 years, per year

−2.9%

Largest fall, 3 years

−89.5%

Below the peak now

−93.3%

Volatility, 1 year

136.6%

Return with dividends reinvested.

Key figures

P/E

4.8

P/B

4.0

Dividend yield

0.0%

Return on equity

+84.0%

Net margin

+54.4%

Market value

37 m USD

Quality, value and trend

Where Sprint Bioscience stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value55

The price measured against earnings, assets and cash flow. Better than 55% of Nordic stocks.

Trend80

The price development over the past year. Better than 80% of Nordic stocks.

Combined95

Quality, value and trend together. Better than 95% of Nordic stocks.

About Sprint Bioscience

Sprint Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 32 employees.

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis